| Mar 23, 2026 | Congruence Therapeutics | $39.5M Other Equity | DIMENSION, OrbiMed | Amplitude Ventures, BDC Capital, Investissement Québec, Lumira Ventures, Silver Arc Private Capital |
| Sep 4, 2025 | Congruence Therapeutics | $32.0M Other Equity | — | Alexandria Venture Investments, Nancy Harrison, BDC Capital, Investissement Québec, Daniel Hétu, OrbiMed, Silver Arc Private Capital |
| Apr 1, 2024 | Alterome Therapeutics | $130.0M Series B | Josh Richardson | Andera Partners, Nextech Invest, OrbiMed, venBio, Vida Ventures, Boxer Capital, Uwe Schoenbeck, Colt Ventures, Digitalis Ventures, Invus, Nextech Invest |
| Jul 1, 2023 | Septerna | $150.0M Series B | Jake Simson | RA Capital, Samsara BioCapital, Sanofi Ventures, Third Rock Ventures, BVF Partners, Casdin Capital, Catalio Capital Management, Deep Track Capital, Goldman Sachs, Invus, Logos Capital, Mirae Asset, Solus Capital, Vertex Ventures HC, Woodline Partners |
| Aug 1, 2021 | Dice Therapeutics | $60.0M Series C | RA Capital Management, Sands Capital | RA Capital, Samsara BioCapital, Versant Ventures, Asymmetry Capital Management, Deep Track Capital, Eventide Asset Management, Janus Henderson Investors, Logos Capital, New Leaf Venture Partners, Northpond Ventures, Osage University Partners, Soleus Capital |
| May 1, 2021 | Nuvalent | $140.0M Series B | Bain Capital Life Sciences | Abingworth, Deerfield Management, MRL Ventures Fund, RiverVest, SV Health Investors, Avoro Capital Advisors, Boxer Capital, Fairmount, Fidelity Management & Research Company, Janus Henderson Investors, Logos Capital, Venrock, Viking Global Investors, Wellington Management |
| Apr 1, 2021 | C2i Genomics | $100.0M Series B | Casdin Capital | Album VC, NFX, Alexandria Venture Investments, Duquesne Family Office, Gordon Asset Management, iGlobe Partners, LionBird, NFX, Section 32, Silver Lake, The Mark Foundation for Cancer Research |
| Feb 1, 2021 | Vividion Therapeutics | $140.0M Series C | Aaron Davis, Graham Walmsley | ARCH Venture Partners, Cure Ventures, Earlybird Venture Capital, Versant Ventures, Vivo Capital, Avoro Capital Advisors, BlackRock, BVF Partners, Casdin Capital, Mubadala Capital, RA Capital Management, Surveyor Capital, T. Rowe Price Associates, Woodline Partners |
| Jan 1, 2021 | Dice Therapeutics | $80.0M Series C | Jake Simson | RA Capital, Samsara BioCapital, Versant Ventures, Agent Capital, Alexandria Venture Investments, Altitude Life Science Ventures, Asymmetry Capital Management, Eventide Asset Management, New Leaf Venture Partners, Northpond Ventures, Osage University Partners, Sands Capital, Sanofi Ventures, Soleus Capital |
| Nov 1, 2020 | Elevation Oncology | $65.0M Series B | — | venBio, Steven A. Elms, Boxer Capital, BVF Partners, Andrew Phillips, Janus Henderson Investors, Qiming Venture Partners USA, Samsara BioCapital, Vertex Ventures HC, Vivo Capital |
| Jul 22, 2020 | Elevation Oncology | $32.5M Series A | Steven A. Elms | BVF Partners, Qiming Venture Partners USA, Vertex Ventures HC |
| Jul 1, 2020 | Thrive Earlier Detection | $260.0M Series B | Section 32, Eli Casdin | Acrew Capital, CRV, GreatPoint Ventures, Mubadala, Polaris Partners, Third Rock Ventures, Trucks Venture Capital, VZVC, Bain Capital Life Sciences, Brown Advisory, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Perceptive Advisors, Rock Springs Capital, Sands Capital, T. Rowe Price Associates |
| Dec 17, 2019 | ArcherDX | $55.0M Series C | Michael Altman | ArrowMark Partners, Boulder Ventures, Longwood Fund, PBM Capital, Redmile Group, Sands Capital, Soleus Capital |
| Feb 1, 2019 | Peloton Therapeutics | $150.0M Series E | Derek DiRocco | 305 Ventures, Foresite Capital, RA Capital, The Column Group, Gregory Bailey, BVF Partners, Curative Ventures, EcoR1 Capital, Eventide Asset Management, Nextech Invest, OrbiMed, Tichenor Ventures, Topspin Fund, Vida Ventures |
| Aug 13, 2018 | Orchard Therapeutics | $150.0M Series C | Elise Wang | Agent Capital, ArrowMark Partners, Cormorant Asset Management, Cowen Healthcare Investments, Foresite Capital, Ghost Tree Capital Group, Medison Ventures, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Healthcare, Temasek, Venrock |
| Mar 1, 2018 | IDEAYA Biosciences | $94.0M Series B | — | 5AM Ventures, Andreessen Horowitz, Canaan Partners, Hatteras Venture Partners, Nextech Invest, Edward Hu, Boxer Capital, Kanishka Pothula, Canaan Partners, Celgene, Vineeta Agarwala, Thilo Schroeder, Perceptive Advisors, Nisha Marathe, WuXi Healthcare Ventures |
